{
    "nctId": "NCT03413761",
    "briefTitle": "Antioxidant Supplements, Genetics and Chemotherapy Outcomes",
    "officialTitle": "Antioxidant Supplements, Genetics and Chemotherapy Outcomes",
    "overallStatus": "COMPLETED",
    "conditions": "Node Positive Breast Cancer, Node Negative Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 1771,
    "primaryOutcomeMeasure": "Epidemiologic Questionnaire",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed diagnosis of operable Stage 1, II, or III invasive breast cancer with known estrogen or progesterone receptor status\n* high risk by meeting at least one of the following criteria:\n\n  1. tumor \\>= 2 cm in greatest diameter\n  2. one or more axillary or intramammary nodes are involved by metastatic breast cancer\n* had either a modified radical mastectomy or local excision of all tumors plus axillary node dissection or sentinel node resection\n* not received prior chemotherapy or radiation therapy for the current malignancy\n* no history of congestive heart failure or angina pectoris\n* normal creatinine and bilirubin, alkaline phosphatase and SGOT or SGPT 2 x the institutional upper limits of normal\n* ANC greater than or equal to 1,200 ul and platelet count of greater than or equal 100,000 U1\n* No previous malignancies\n* Age 18 or greater\n* Performance status of 0 -2 by Zubrod criteria\n* HIV negative (if known)",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}